Scientists and patient advocates have largely overlapping agendas, but, ultimately, their agendas diverge, said Fran Visco, president of the National Breast Cancer Coalition, the organization that ushered in a new era in the politics of cancer research and delivery of care.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
